Baicalein ameliorated the upregulation of striatal glutamatergic transmission in the mice model of Parkinson's disease

Brain Research Bulletin

Volumn 103, Issue , 2014, Pages 54-59

  Xue, Xinhong ^a   Liu, Hong ^a   Qi, Lifeng ^a   Li, Xueli ^a   Guo, Cunju ^a   Gong, Dianrong ^a   Qu, Huaiqian ^a  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

Baicalein; Glutamatergic transmission; Parkinson's disease; Rotarod task; Striatum

Indexed keywords

AMPA RECEPTOR; BAICALEIN; BETA ACTIN; GLUTAMATE RECEPTOR; GLUTAMIC ACID; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FLAVANONE DERIVATIVE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PARKINSON DISEASE; PRESYNAPTIC NERVE; PRIORITY JOURNAL; STRIATAL GLUTAMATERGIC TRANSMISSION; SUBSTANTIA NIGRA; SYNAPTOSOME; UPREGULATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; INTOXICATION; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; SYNAPTIC TRANSMISSION;

ANIMALS; CORPUS STRIATUM; CYTOKINES; DISEASE MODELS, ANIMAL; FLAVANONES; GLUTAMIC ACID; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; MPTP POISONING; RECEPTORS, AMPA; SYNAPTIC TRANSMISSION; UP-REGULATION;

EID: 84898544146     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2014.02.004     Document Type: Article

References (29)

1. Azdad K., Chavez M., Don Bischop P., Wetzelaer P., Marescau B., De Deyn P.P., Gall D., Schiffmann S.N. Homeostatic plasticity of striatal neurons intrinsic excitability following dopamine depletion. PLoS ONE 2009, 4:e6908.
2. Bagetta V., Ghiglieri V., Sgobio C., Calabresi P., Picconi B. Synaptic dysfunction in Parkinson's disease. Biochemical Society Transactions 2010, 38:493-497.
3. Bagetta V., Sgobio C., Pendolino V., Del Papa G., Tozzi A., Ghiglieri V., Giampa C., Zianni E., Gardoni F., Calabresi P., Picconi B. Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2012, 32:17921-17931.
4. Bie B., Zhu W., Pan Z.Z. Rewarding morphine-induced synaptic function of delta-opioid receptors on central glutamate synapses. Journal of Pharmacology and Experimental Therapeutics 2009, 329:290-296.
5. Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. Journal of Neuroimmune Pharmacology: The Official Journal of the Society on NeuroImmune Pharmacology 2013, 8:189-201.
6. Borrajo A., Rodriguez-Perez A.I., Diaz-Ruiz C., Guerra M.J., Labandeira-Garcia J.L. Microglial TNF-alpha mediates enhancement of dopaminergic degeneration by brain angiotensin. Glia 2014, 62:145-157.
7. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain: A Journal of Neurology 1993, 116(Pt 2):433-452.
8. Calabresi P., Di Filippo M., Ghiglieri V., Tambasco N., Picconi B. Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurology 2010, 9:1106-1117.
9. Centonze D., Gubellini P., Picconi B., Calabresi P., Giacomini P., Bernardi G. Unilateral dopamine denervation blocks corticostriatal LTP. Journal of Neurophysiology 1999, 82:3575-3579.
10. Day M., Wokosin D., Plotkin J.L., Tian X., Surmeier D.J. Differential excitability and modulation of striatal medium spiny neuron dendrites. Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2008, 28:11603-11614.
11. Fan G.W., Zhang Y., Jiang X., Zhu Y., Wang B., Su L., Cao W., Zhang H., Gao X. Anti-inflammatory activity of baicalein in LPS-stimulated RAW264.7 macrophages via estrogen receptor and NF-kappaB-dependent pathways. Inflammation 2013, 36:1584-1591.
12. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991, 252:851-853.
13. Lee E., Park H.R., Ji S.T., Lee Y., Lee J. Baicalein attenuates astroglial activation in the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model by downregulating the activations of nuclear factor-kappaB, ERK, and JNK. Journal of Neuroscience Research 2014, 92:130-139.
14. Li F.Q., Wang T., Pei Z., Liu B., Hong J.S. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. Journal of Neural Transmission 2005, 112:331-347.
15. Li F., Zhu S., Wu C., Yan C., Liu Y., Shugan L. Neuroinflammation and cell therapy for Parkinson's disease. Frontiers in Bioscience 2011, 3:1407-1420.
16. 2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends in Neurosciences 2007, 30:126-134.
17. Ma G.F., Chen S., Yin L., Gao X.D., Yao W.B. Exendin-4 ameliorates oxidized-LDL-induced inhibition of macrophage migration in vitro via the NF-kappaB pathway. Acta Pharmacologica Sinica 2014, 35:195-202.
18. Manabe T., Wyllie D.J., Perkel D.J., Nicoll R.A. Modulation of synaptic transmission and long-term potentiation: effects on paired pulse facilitation and EPSC variance in the CA1 region of the hippocampus. Journal of Neurophysiology 1993, 70:1451-1459.
19. Massano J., Bhatia K.P. Clinical approach to Parkinson's disease: features, diagnosis, and principles of management. Cold Spring Harbor Perspectives in Medicine 2012, 2:a008870.
20. Moriguchi S., Yabuki Y., Fukunaga K. Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. Journal of Neurochemistry 2012, 120:541-551.
21. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of parkinson's disease: focus on astrocytes. Molecular Neurobiology 2014, 49:28-38.
22. Qi Z., Yin F., Lu L., Shen L., Qi S., Lan L., Luo L., Yin Z. Baicalein reduces lipopolysaccharide-induced inflammation via suppressing JAK/STATs activation and ROS production. Inflammation Research: Official Journal of the European Histamine Research Society 2013, 62:845-855.
23. Rim H.K., Yun C.H., Shin J.S., Cho Y.W., Jang D.S., Ryu J.H., Park H., Lee K.T. 5,6,7-Trimethoxyflavone suppresses pro-inflammatory mediators in lipopolysaccharide-induced RAW 264. 7 macrophages and protects mice from lethal endotoxin shock. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association 2013, 62:847-855.
24. Roy A., Ghosh A., Jana A., Liu X., Brahmachari S., Gendelman H.E., Pahan K. Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease. PLOS ONE 2012, 7:e38113.
25. Tai W., Ye X., Bao X., Zhao B., Wang X., Zhang D. Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models. Neuropharmacology 2013, 75:201-212.
26. Warre R., Thiele S., Talwar S., Kamal M., Johnston T.H., Wang S., Lam D., Lo C., Khademullah C.S., Perera G., Reyes G., Sun X.S., Brotchie J.M., Nash J.E. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiology of Disease 2011, 41:591-604.
27. Xu J., Zhang Y., Xiao Y., Ma S., Liu Q., Dang S., Jin M., Shi Y., Wan B., Zhang Y. Inhibition of 12/15-lipoxygenase by baicalein induces microglia PPARbeta/delta: a potential therapeutic role for CNS autoimmune disease. Cell Death & Disease 2013, 4:e569.
28. Yabuki Y., Ohizumi Y., Yokosuka A., Mimaki Y., Fukunaga K. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice. Neuroscience 2014, 259:126-141.
29. Yang L.P., Sun H.L., Wu L.M., Guo X.J., Dou H.L., Tso M.O., Zhao L., Li S.M. Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy. Investigative Ophthalmology & Visual Science 2009, 50:2319-2327.